跳至主要内容
临床试验/CTRI/2025/04/085835
CTRI/2025/04/085835尚未招募3 期

Role of IV ketamine in suicidal risk reduction in patients with suicidality attending psychiatry department in a tertiary care hospital, a placebo based, double blinded, randomized controlled trial.

Rajashree Mohanta1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年5月18日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
80
试验地点
1
主要终点
remission of suicidal ideation measured in BSS scale

研究概览

简要总结

in this trial we are going to verify the effectiveness of the iv ketamine in patients with suicidal ideation in indian population. this is a singe blinded trial. every adverse effect was monitered by the investigator.

研究设计

研究类型
Interventional

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • having suicidal ideation measured in BSS Scale.

排除标准

  • cardiovascular disease intracranial hypertension head injury pregnancy breast feeding allergy to ketamin delrium substance use disorder except nicotine major psychotic disorder.

结局指标

主要结局

remission of suicidal ideation measured in BSS scale

时间窗: baseline | 1 week | 2 week | 4 week | 6 months

次要结局

未报告次要终点

研究者

发起方
Rajashree Mohanta
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Rajashree Mohanta

SCB Medical college and Hospital

研究点 (1)

Loading locations...

相似试验